Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...
The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...
The Nasdaq Composite Index ( ^IXIC -4.00%) is now squarely in correction territory. But stock market corrections have one key ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...
Shares of Vertex Pharmaceuticals Inc. VRTX advanced 1.11% to $491.64 Wednesday, on what proved to be an all-around favorable ...
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Representative Jefferson Shreve (R-Indiana) recently bought shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). In a filing disclosed on March 09th, the Representative disclosed that they had ...
A month has gone by since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have added about 7.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...
Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...
Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...